

EPA Office of Research and Development

# HOMELAND SECURITY RESEARCH



## COVID-19 Research: Ozone and Aerosol Treatment



**HSRP Webinar Series  
August 12, 2021**

***Lukas Oudejans, Ph.D.  
Katherine Ratliff, Ph.D.***

*ORD's Center for Environmental Solutions and Emergency Response*



## Regulatory

- Pesticide Registration (FIFRA)
- FIFRA Enforcement
- Test Method Development


## Response

- Cleanup Guidance
- Technical Support
- Preparedness/Mitigation

## Research

- Aerosol Treatment
- Surface Cleaning and Disinfection
- Pesticide Application
- Pesticide Devices
- Residual Antimicrobial Coatings

- Ozone: Disinfection of Surfaces
  - Research Objectives
  - Background
  - Setup and Test Matrix
  - Results
- Aerosol Treatment Research
  - Background and Research Objectives
  - Methods and Test Chamber
  - Results
    - Bipolar Ionization
    - Grignard Pure
    - 3-Stage Air Filtration and Purification System





# Research Objectives: Evaluating Alternative Surface Disinfection Methods

Assessment of methods to disinfect challenging materials (e.g., porous surfaces) and application methods suitable for large or complex areas

- Supplemental methods to regular surface disinfection approaches

## Initial selection:

1. UV light – *webinar on January 21, 2021*
2. **Ozone** – **discussed in this webinar**
3. Steam – *research in progress*

<https://www.epa.gov/emergency-response-research/covid-19-uv-c-devices-and-methods-surface-disinfection-webinar>


## Disinfection Performance Goal:

- Three (3)-log reduction\* (99.9%) in viable/infective virus post-treatment

\*: *Virucidal Claim: A product should demonstrate a  $\geq 3 \log_{10}$  reduction on every surface in the presence or absence of cytotoxicity.*  
- EPA 810.2200 Disinfectants for Use on Environmental Services




- Ozone is a strong oxidizing agent and inhalation carries a health risk (damage to respiratory system)
- Ozone Immediately Dangerous to Life and Health (IDLH) is 5 ppm
- NIOSH recommended exposure limit (REL) for ozone is 0.1 ppm [OSHA PEL 8h-TWA is also 0.1 ppm]
- Ozone is our friend in the stratosphere but a pollutant in the air we breathe



Ozone

# Ozone as a Disinfectant

- Antiviral and antimicrobial properties of ozone are well studied
  - Mostly with ozone in water
- At start of the study, data on disinfection ability of ozone against SARS-CoV-2 was limited to small number of studies
- Need more information for more realistic field conditions (e.g., on various materials, inoculum types, realistic exposure conditions)
- Large variability in reported inactivation rates due to different test conditions



Ozone




# Ozone Setup and Generation



**Test chamber within Bio Safety Level (BSL)-3 facility**



**Rack to hold coupons;  
added fan to promote air  
circulation**



**Example of layout Coupons**




**Ozone Generator  
Queenaire QT Storm  
(Corona discharge)**



# Ozone Test Matrix

	SARS-CoV-2
Ozone Concentrations	10 ppm or 20 ppm
Relative Humidity	50% or 70-80%
Contact Times	30 and 60 minutes
Materials (2.5 cm x 4.0 cm)	301 Stainless Steel ABS Plastic Bus Seat Fabric (pile; 85% wool, 15% nylon)
Inoculum Application	10 x 10 $\mu$ L Droplets
Inoculum Matrix	Tissue Culture (TC) Media with 5% FBS or Simulated Saliva (ASTM)
Inoculum Presence	Wet / Dry Droplets



- 
- A large, solid blue arrow pointing downwards, positioned to the left of the list items.
- Aseptic retrieval of material coupon followed by placement into sterile conical tubes with extraction buffer
  - Vortexing (2 min)
  - For SARS-CoV-2, samples were split with one part stored for RV-PCR analysis (*in progress*)
  - Culture on a well plate titer with varying dilutions of the testing fluid are added to the wells.
  - SARS-CoV-2 Eluents were tested for viable virus by cell culture (Median Tissue Culture Infectious Dose, TCID50 assay)

## **Efficacy:**

Log Reduction (LR) = Mean  $\log_{10}$  recovery (Positive Controls) - Mean  $\log_{10}$  recovery (Test Coupons)

Prior to the ozone testing, we demonstrated that:

- Sufficient SARS-CoV-2 high recoveries (low  $10^5$  PFU/coupon) can be obtained from all materials
  - Typically, lower recoveries for SARS-CoV-2 in simulated saliva (high  $10^3$  PFU/coupon)
- No cytotoxicity of materials observed
- Based on TCID<sub>50</sub> procedures, a detection limit of 6.3 virions/coupon was established




# Ozone Results at High RH

## SARS-CoV-2 Inactivation by Ozone

10 ppmv, 70-80% RH

Wet Droplets at Start of Exposure




## Wet droplets at start of ozone exposure; (24 °C; 70-80% RH)

- Positive control recoveries were  $>10^5$  PFU/sample (lower [ $10^4$ ] for sim. saliva, 60 min)
- Ozone can inactivate the SARS-CoV-2 virus
- A 2- to 3- log reduction can be obtained
  - Residual virus remaining on surfaces except for 60 min Stainless steel, simulated saliva
- No noticeable material dependence
- 30 min timepoint appears twice as it was the longest time for Test1 and shortest for Test2
  - High reproducibility of tests (except for one datapoint – bus seat fabric)



# Ozone Results at High RH

SARS-CoV-2 Inactivation by Ozone  
10 ppmv, 70-80% RH  
Dried Droplets at Start of Exposure




## Dried droplets at start of ozone exposure; High RH (24 °C):

- Positive control recoveries were  $>10^4$  PFU/sample for tissue culture media;  $>10^3$  PFU/sample for simulated saliva
- Minimal (less than 1 log reduction;  $<90\%$ ) inactivation of the SARS-CoV-2 virus
- No appreciable improvement in efficacy for longer exposure times
- No noticeable material dependence
- 30 min timepoint appears twice as it was the longest time for Test1 and shortest for Test2



# Ozone Results at High RH

Side by side comparison of results for wet droplets vs dried droplets at start of ozone exposure








# Ozone Results at Lower RH

SARS-CoV-2 Inactivation by Ozone  
10 ppmv data, 50% RH



## Wet droplets and dried droplets at start of ozone exposure; (24 °C; 50% RH)


- Positive control recoveries were  $>10^5$  PFU/sample (lower [ $10^4$  range] for sim. saliva)
- Achieved a 3-log reduction level (99.9%) after 1 hour at 10 ppmv ozone for initial wet droplets for most material/media combinations
- Again, a significant difference in log reduction between wet and dried droplets with no noticeable material dependence
- Dataset at 20 ppmv ozone (not shown; same exposure times) show similar results in efficacy but the larger variability in recoveries from controls makes interpretation difficult




# Ozone Disinfection Conclusions

- Inactivation of the SARS-CoV-2 virus on various surfaces via ozone fumigation (10 ppm; 1 hour) was observed [2-3 log reduction (99-99.9%)]
- SARS-CoV-2 is noticeably more difficult to inactivate when present in dried droplets on surfaces (most likely operational scenario)
- Lack of water (in dried droplets) diminishes inactivation
- Increase in RH (50% vs 70-80%) did not improve inactivation for dried droplets
- Wet droplet results are consistent with ozone inactivation data against SARS-CoV-2

- Ozone: Disinfection of Surfaces
  - Research Objectives
  - Background
  - Setup and Test Matrix
  - Results
- Aerosol Treatment Research
  - Background and Research Objectives
  - Methods and Test Chamber
  - Results
    - Bipolar Ionization
    - Grignard Pure
    - 3-Stage Air Filtration and Purification System




- Studies have documented the spread of COVID-19 in enclosed spaces (e.g., buses, hospital rooms, restaurants, offices)
- Growing focus on the transmission of COVID-19 via aerosolized SARS-CoV-2
- Increasing focus on **air treatment technologies**
  - Many technologies are devices, which are not registered by EPA.
- **Challenges:**
  - Growing need and desire repopulate indoor spaces (schools, offices, restaurants, public transit, events and gatherings, etc.)
  - Social distancing not always feasible
  - Many air cleaning technologies on the market, lack of independent testing data



- How effective are commercially-available aerosol treatment technologies at reducing concentrations of infectious SARS-CoV-2 in the air?

- **Research Goals:**


- Assess efficacy of aerosol treatment products and devices at a real-world scale
- Develop reliable and standardizable methods for testing air treatment technologies
- Establish expertise to extrapolate understanding of treatment technologies to inform estimation of efficacy of novel, untested technologies



Niazi et al. (2020), *Environmental Pollution*




- UVC devices: e.g., upper-room germicidal UVC, in-duct UVC
- Chemical products and devices: in-room or in-duct; e.g., low-concentration ozone, low-concentration hydrogen peroxide, bipolar ionization
- Physical removal: e.g., MERV-13 and specialized filters, portable air cleaners
- Combinations of the above



*Focus on air treatment technologies and methods that can be continuously operating in occupied spaces (in-room or in-duct)*






- Evaluate efficacy of technologies against non-pathogenic virus (MS2)
  - Expected to be more resistant to chemical inactivation than SARS-CoV-2



[https://upload.wikimedia.org/wikipedia/commons/thumb/7/7e/Ms2capsid\\_surface.png/1024px-Ms2capsid\\_surface.png](https://upload.wikimedia.org/wikipedia/commons/thumb/7/7e/Ms2capsid_surface.png/1024px-Ms2capsid_surface.png)



# Aerosol Treatment: Methods

						
	MS2	Phi6	MHV	229E	SARS-CoV-2	
Enveloped?	No	Yes	Yes	Yes	Yes	spores
Host	Bacteria ( <i>E. coli</i> )	Bacteria ( <i>P. syringae</i> )	Mice	Humans	Humans	mycobacteria
Genus	Levivirus	Cystovirus	Betacoronavirus	Alphacoronavirus	Betacoronavirus	Non-enveloped viruses
BSL	1	1	2	2	3	Fungi
Advantage	High resistance & persistence, fast and easy analysis	Moderate resistance & persistence, fast and easy analysis	Same genus as SARS-CoV-2, non-human pathogen	Same Family as SARS-CoV-2	Actual agent of COVID-19	Gram-negative bacteria
Surrogate?	Comparison in progress			Regulatory surrogate		Gram-positive bacteria
						Enveloped viruses

Increasing Resistance

Increasing Resistance

- Evaluate efficacy of technologies against non-pathogenic virus (MS2)
  - Aerosolized using 6-jet Collison nebulizers
    - Count median diameter of aerosolized particles ~45 nm at the beginning of each test; increases in size over duration of test (100 nm at 120 min)
  - Air sampling:
    - SKC BioSamplers (enumerated via plaque assay)
    - CCDC-CBC TACBIO 2 (real-time)
  - Surface sampling:
    - Inoculated 2 cm x 4 cm stainless-steel coupons
    - Clean stainless-steel coupons for deposition
    - 5 pairs co-located on chamber floor
  - Onsite microbiology lab
  - Particle size & count measurements





- Evaluate efficacy of technologies against non-pathogenic virus (MS2)
- Utilize specialized Aerosol Test Facility in Research Triangle Park, NC
  - Large air treatment test chamber 10 x 12 x 25 ft (3000 ft<sup>3</sup>)
  - Controlled temperature / humidity
    - $22 \pm 2$  °C
    - 30-35 % RH
  - Mixing fans









# Aerosol Treatment: Methods

- Evaluate efficacy of technologies against non-pathogenic virus (MS2)
- Utilize specialized Aerosol Test Facility in Research Triangle Park, NC
- Mock HVAC system designed and installed for evaluating technologies
  - Negative air machine simulates mock cold air return with adjustable flow
    - 350 CFM, ~7 air changes per hour
  - Six branches (6") from main line (8"), each outlet fitted with diffuser
  - Galvanized steel duct materials





# Test Chamber & HVAC System






# Aerosol Treatment: Methods

- Evaluate efficacy of technologies against non-pathogenic virus (MS2)
- Utilize specialized Aerosol Test Facility in Research Triangle Park, NC
- Mock HVAC system designed and installed for evaluating technologies

**Testing objective:** Obtain high enough recoveries in control conditions throughout duration of testing to demonstrate a  $3\text{-log}_{10}$  reduction







# Aerosol Treatment: Technologies

Technology Type	Intended Use
Bipolar Ionization	Installed in-duct; intended for residential, commercial, industrial, education, health care settings
Grignard Pure (active ingredient: Triethylene Glycol)	Dispersed either in-room or in-duct; intended for use in indoor spaces for essential economic activities as determined by the state; e.g., health care, transportation, food processing
Knorr 3-Stage System: Electrostatic Filter, UVC, and Bipolar Ionization modules	3-stage air filtration and purification system designed to be installed (either new or as retrofit) in the HVAC system of rail transit vehicles; plan to evaluate components operating together & in isolation
Photocatalytic	General indoor use; transit vehicles
Filtration	For use in residential, commercial, transit settings



# Aerosol Treatment: Technologies


	Technology Type	Intended Use
✓	Bipolar Ionization	Installed in-duct; intended for residential, commercial, industrial, education, health care settings
✓	Grignard Pure (active ingredient: Triethylene Glycol)	Dispersed either in-room or in-duct; intended for use in indoor spaces for essential economic activities as determined by the state; e.g., health care, transportation, food processing
✓	Knorr 3-Stage System: Electrostatic Filter, UVC, and Bipolar Ionization modules	3-stage air filtration and purification system designed to be installed (either new or as retrofit) in the HVAC system of rail transit vehicles; plan to evaluate components operating together & in isolation
*	Photocatalytic	General indoor use; transit vehicles
*	Filtration	For use in residential, commercial, transit settings

*\* Testing ongoing in August 2021*




# Bipolar Ionization Device

- Bipolar ionization generates charged ions that react with airborne contaminants, including viruses
- Cold plasma bipolar ionization device selected for evaluation
  - Sized to treat 2000-4000 ft<sup>2</sup> of living space
- Installed in-duct
- 30 to 90-minute ion buildup times in chamber prior to testing, resulting in ion counts of 1000-6000 ions/cm<sup>3</sup>



duct location for  
technology installation


# Bipolar Ionization Device





# Bipolar Ionization Device


- Average  $\log_{10}$  reductions in aerosolized MS2 from initial tests range from -0.16 to 0.85 throughout test duration
- No additional virus recovered from surfaces
- No surface inactivation observed



- Antimicrobial air treatment product
  - Section 18 Emergency Exemptions for indoor use in GA, MD, NV, PA, TN, TX
- Triethylene glycol (TEG) active ingredient
  - Commonly used in theatrical fog machines
  - Historic publications on air disinfection date to 1940's
  - 1.2 – 1.5 mg/m<sup>3</sup> concentration of TEG during testing (NIOSH Method 5523)
- Two different test sequences evaluated:
  - Introduce product into aerosolized MS2
  - Introduce MS2 into product in chamber already at target concentration



# Grignard Pure









# Grignard Pure

## Product introduced into MS2



## MS2 introduced into Product




\* 2 of 4 replicates at LOD



# Grignard Pure

- Higher calculated efficacy when MS2 aerosolized with product present in test chamber
- Surface inactivation observed on inoculated coupons
  - GP into MS2: average  $\log_{10}$  reduction  $1.6 \pm 0.4$  PFU/coupon
  - MS2 into GP: average  $\log_{10}$  reduction  $1.9 \pm 0.2$  PFU/coupon
- Reduced MS2 recoveries on deposition coupons



\* Some replicates at LOD (1.0 log<sub>10</sub> PFU/Sample)


# 3-Stage Air Filtration & Purification

- System developed by Knorr Brake Company for transit vehicles
  - Electrostatic filter – Merak Intense Field Dielectric (MIFD) filter
  - Bipolar ionization – Merak Dielectric Barrier Discharge (MDBD) device
  - UV-C radiation – low-pressure mercury vapor lamp (wavelength = 254 nm)
- Test unit in center of chamber
  - Knorr blower: ~25 air changes per hour
  - Recirculating HVAC still operating
- Controls with and without MIFD arrest filter






# 3-Stage Air Filtration & Purification






# 3-Stage Air Filtration & Purification

Control With Filter



Control Without Filter



MIFD – Electrostatic Filter  
MDBD – Bipolar Ionization  
UV – 254 nm UV-C Source


■ MIFD ■ MIFD + MDBD ■ MIFD + MDBD + UV ■ MDBD + UV ■ MDBD





# 3-Stage Air Filtration & Purification

- Greater particle capture with MIFD operating
- MIFD arrest filters capture  $\sim 0.5 \log_{10}$  particles alone (without applied charge)
- MDBD and UVC components appear to contribute to MS2 inactivation
  - Reduced particle capture, but efficacy against MS2 is similar when MIFD is operating





# Aerosol Treatment Conclusions

- Efficacy of different types of air treatment technologies can be evaluated using similar testing methodologies
  - Demonstrated efficacies range from < 1-log reduction to > 3-log reduction, depending on technology type and test sequence
- Testing at large scale needed to extrapolate results to real world
  - Still need to consider many other factors, such as temperature/humidity, HVAC system design, air change rates, etc.
- Design of control conditions impacts calculated efficacy
- Next steps: *evaluate photocatalytic devices and filters (August 2021)*



# Acknowledgements

- John Archer, Lance Brooks, Worth Calfee, Shawn Ryan, and members of EPA Project Teams
- EPA Program Offices
  - Office of Chemical Safety and Pollution Prevention
  - Office of Land and Emergency Management
- EPA Regional Offices
- EPA ORD Safety, Health, and Environmental Management
- NYC MTA and LA Metro
- Battelle Task Order 68HERC20F0241 (ozone studies):  
Will Richter, Michelle Sunderman, Megan Howard
- Jacobs Technology Group Task Order 68HERC21F0063 (aerosol treatment studies):
  - Aerosol Test Facility: Jerome Gilberry, Adam Hook, Robert Yaga, Will Schoppman, Lydia Brouwer, Brittany Thomas
  - Homeland Security and Materials Management Microbiology Lab
  - Mechanical Fabrication Shop



# Points of Contact

Lukas Oudejans, [Oudejans.Lukas@epa.gov](mailto:Oudejans.Lukas@epa.gov)

Katherine Ratliff, [Ratliff.Katherine@epa.gov](mailto:Ratliff.Katherine@epa.gov)

ORD/CESER/HSMMD



<https://www.epa.gov/covid19-research>

**DISCLAIMER:** The United States Environmental Protection Agency (EPA), through its Office of Research and Development, funded and managed the research described. This presentation was peer and administratively reviewed and has been approved for presentation as an Environmental Protection Agency document. It does not necessarily reflect the views of the Environmental Protection Agency. No official endorsement should be inferred. This presentation includes photographs of commercially-available products. The photographs are included for purposes of illustration only and are not intended to imply that EPA approves or endorses the product or its manufacturer. EPA does not endorse the purchase or sale of any commercial products or services.

Data presented herein did not undergo a formal quality assurance review as outlined in “U.S. EPA Office of Research and Development’s Quality Management Plan for Scientific Research”. If these data are included in future EPA reports or other publications, they will be subjected to this review.